Bicara Therapeutics (NASDAQ:BCAX) Trading Up 5.7% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares rose 5.7% during trading on Thursday . The stock traded as high as $13.66 and last traded at $13.85. Approximately 26,971 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 457,999 shares. The stock had previously closed at $13.10.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BCAX shares. Wedbush reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. HC Wainwright lifted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Stock Up 0.4 %

The firm has a fifty day moving average price of $12.98.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of BCAX. California State Teachers Retirement System bought a new position in Bicara Therapeutics in the 4th quarter worth $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics during the 4th quarter worth about $33,000. Finally, Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth about $35,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.